Review: discontinuation rates are the same for serotonin specific reuptake inhibitors and newer tricyclic and heterocyclic antidepressants


Objective
To determine if the advantage in discontinuation rates of serotonin specific reuptake inhibitors (SSRIs) shown in previous reviews was present when compared with newer tricyclic or heterocyclic antidepressants for the treatment of depression.

Data sources
As part of an ongoing Cochrane Collaboration review, randomised controlled trials were identified by searching Medline for previous reviews that compared SSRIs (fluoxetine, sertraline, paroxetine, and fluvoxamine) with tricyclics and heterocyclics. Additional studies were identified by hand searching 2 journals. If data for discontinuation rates were not complete, the first author was contacted.

Study selection
Trials were selected if they compared tricyclics or heterocyclics with SSRIs for the treatment of depression. Studies of these compounds for other indications were excluded.

Data extraction
Data were extracted on discontinuation rates, type of SSRI used, type of tricyclic or heterocyclic used, patient numbers, and whether the treated patients were >60 to 70 years of age.

Main results
Keywords: Keywords please
Tricyclics and heterocyclics were classified into 1 of 3 groups: reference compounds (imipramine and amitriptyline); newer tricyclics (dothiepin, nortriptyline, desipramine, clomipramine, and doxepin); and heterocyclics (bupropion, mianserin, trazodone, maprotiline, amineptine, and nomifensine). Discontinuation rates were lower for SSRIs compared with tricyclics and heterocyclics combined [p < 0.01]* and compared with reference compounds [p < 0.05]* (table). No differences in discontinuation rates were found when SSRIs were compared with either newer tricyclics (odds ratio [OR] 0.89, 95% CI 0.74 to 1.06) or heterocyclics (OR 1.02, CI 0.78 to 1.35).

Conclusions
Rates of discontinuation are the same for SSRIs and newer tricyclic or heterocyclic antidepressants. The advantage of SSRIs shown in previous reviews is caused by the use of old tricyclics as reference compounds.

Serotonin specific reuptake inhibitors (SSRIs) v tricyclics and heterocyclics combined and reference drugs†

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>SSRIs (weighted EER)</th>
<th>Control (weighted CER)</th>
<th>RRR (95% CI)</th>
<th>Weighted NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discontinuation (combined drugs)</td>
<td>31%</td>
<td>33%</td>
<td>8% (5 to 14)</td>
<td>2.4% (24 to 148)</td>
</tr>
<tr>
<td>Discontinuation (reference drugs)</td>
<td>35%</td>
<td>38%</td>
<td>10% (5 to 16)</td>
<td>3.1% (32 to 159)</td>
</tr>
</tbody>
</table>

†Abbreviations defined in glossary; RRR, ARR, NNT, and CI calculated from data in article.

*p values calculated from data in article.

Source of funding: Medical Research Council Clinical Training Fellowship.

Abstract and commentary also published in Evidence-Based Medicine 1997 Sep-Oct;2:149.

Commentary
The review by Hotopf et al is consistent with previous reviews that show that the dropout rate from treatment for depression with SSRS, which is itself quite substantial at around 30%, is only slightly lower than the dropout rate with tricyclic antidepressants. The relevance of the finding that this difference disappears when SSRIs are compared with “newer” tricyclics or heterocyclics is less clear. The distinction made between older and newer tricyclics is not well established, and other reviews categorise these drugs differently. Evidence from general practice that tricyclics, with the exception of lofepramine, continue to be prescribed in “subtherapeutic” doses in most cases seems to suggest that these drugs are not well tolerated at recommended antidepressant doses. Further investigation is needed into the efficacy of low dose treatment with tricyclics because there is currently inadequate evidence about this issue. Because tricyclics and SSRIs seem to be equally effective, the decision about which to use depends on balancing issues of tolerability, toxicity, and cost. SSRIs are clearly less dangerous in overdose, although the tricyclic lofepramine has a similar advantage. Cost favours tricyclics. The issue of side effects depends on each patient’s situation and symptoms. However, discussion of the relative value of these 2 classes of antidepressants should not obscure the fact that drug treatment, especially in general practice, is not necessarily always appropriate or sufficient.

Joanna Moncrieff
BMedSci, MBBS
Institute of Psychiatry,
London, UK

Review: discontinuation rates are the same for serotonin specific reuptake inhibitors and newer tricyclic and heterocyclic antidepressants

_Evid Based Mental Health_ 1998 1: 21
doi: 10.1136/ebmh.1.1.21

Updated information and services can be found at:
[http://ebmh.bmj.com/content/1/1/21](http://ebmh.bmj.com/content/1/1/21)

_These include:_

**References**
This article cites 3 articles, 3 of which you can access for free at:
[http://ebmh.bmj.com/content/1/1/21#BIBL](http://ebmh.bmj.com/content/1/1/21#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Depressive disorder (570)
- Clinical trials (epidemiology) (989)
- Epidemiology (1570)

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)